| Stéphane Bancel |
Stéphane Bancel is currently the Chief Executive Officer & Director at ModernaTX, Inc., Chief Executive Officer & Director at Moderna, Inc., and Chief Executive Officer at Moderna SpA. He is also a Director at Indigo Ag, Inc. and Generate Biomedicines, Inc., a Special Partner at Flagship Pioneering, a Member-Supervisory Board at QIAGEN GmbH and QIAGEN Srl, and a Trustee at the Museum of Science. Formerly, Mr. Bancel served as the Chief Executive Officer at bioMérieux SA from 2007 to 2011. He was also the Chief Executive Officer at Moderna Holding BV, Chairman at BG Medicine, Inc. from 2010 to 2015, and Executive Director-Global Manufacturing Strategy at Eli Lilly & Co. from 2000 to 2006. Additionally, he held positions as a Director at Biotheranostics, Inc., Targanta Therapeutics Corp., and Tafkak, Inc., and as the Managing Director at Eli Lilly Benelux SA. He served as an Independent Director at Syros Pharmaceuticals, Inc. from 2013 to 2017 and as an Independent Member-Supervisory Board at QIAGEN NV from 2013 to 2021. Mr. Bancel was also a Principal at Eli Lilly & Co. Ltd.Mr. Bancel obtained a graduate degree from the University of Minnesota and École Centrale Paris. He also holds an MBA from Harvard Business School. |
| Brad Miller |
Brad Miller is currently the Chief Information Officer at Moderna, Inc. He previously worked as the Chief Information Officer-Enterprise Products at Capital One Financial Corp. and as the Executive Vice President-Operations & Technology at Citibank, Inc. Mr. Miller completed his undergraduate degree at The University of Waterloo and his graduate degree at The University of Nottingham. |
| Jerh Collins |
Jerh Collins is currently the Chief Technical Operations & Quality Officer at Moderna, Inc. Prior to this, he has no other job history mentioned in the provided context information. He has an undergraduate and doctorate degree from University College Cork. |
| José M. Vega |
José M. Vega is currently the Chief Safety Officer at Moderna, Inc. Prior to this, he held the same position at Merck Research Laboratories Massachusetts LLC from 2013 to 2021. Vega received his graduate degree from Harvard University, his doctorate from Harvard Medical School, and his undergraduate degree from Harvard College. |
| Melanie Ivarsson |
Melanie Ivarsson is currently the Director at Loqus23 Therapeutics Ltd. and the Chief Development Officer at Moderna, Inc. Previously, she worked as the Vice President & Head-Global Clinical Operations at Takeda Pharmaceuticals U.S.A., Inc. Dr. Ivarsson holds a doctorate from the University of Bristol and an MBA from MIT Sloan School of Management. |
| Tracey Franklin |
Tracey Franklin is currently the Chief Human Resources Officer at Moderna, Inc. She previously worked at Merck & Co., Inc. as the Chief Talent & Strategy Officer and Vice President. Franklin has a graduate degree from Fairleigh Dickinson University and an undergraduate degree from The Pennsylvania State University. |
| James M. Mock |
James M. Mock is currently the Chief Financial Officer at Moderna, Inc. Prior to his current position, he served as the Chief Financial Officer & Senior Vice President at Revvity, Inc. from 2018 to 2022. He also held the position of Vice President at GE Aerospace from 2015 to 2018 and Chief Financial Officer & Vice President at Baker Hughes Energy Services LLC from 2014 to 2015. Mr. Mock completed his undergraduate degree at St. Lawrence University. |
| Noubar B. Afeyan |
Noubar B. Afeyan founded Epitome Biosystems, Inc. in 2003, Celera Group in 1998, Indigo Ag, Inc. in 2013, and various other companies. Dr. Afeyan also founded Invaio Sciences, Inc., Senda Biosciences, Inc., Armenian Assembly of America, Inc., where he worked as Director, and various other companies. Dr. Afeyan also currently works at Alltrna, as Chairman, Profound Therapeutics, as Chairman, YourBio Health, Inc., as Director, and various other companies. Dr. Afeyan also formerly worked at Codon Devices, Inc., as Chairman from 2004 to 2010, Forum Mondial de L'Economie, as Chairman-Global Agenda Council, The World Economic Forum USA, Inc., as Chairman-Global Agenda Council, and various other companies. Dr. Afeyan received his undergraduate degree in 1983 from McGill University and doctorate degree in 1987 from Massachusetts Institute of Technology. |
| Kate Cronin |
Kate Cronin is currently the Chief Brand Officer at Moderna, Inc. Prior to her current position, she worked as Co-President & Chief Executive Officer at Ogilvy Healthworld and as Global Managing Director at Ogilvy Public Relations Worldwide, Inc. She obtained an undergraduate degree from Smith College. |
| Stephen Hoge |
Stephen Hoge is currently the President of ModernaTX, Inc. and Moderna, Inc. He previously served as an Independent Director at Axcella Health, Inc. from 2014 to 2022 and as a Partner at McKinsey & Co., Inc. from 2010 to 2012. Dr. Hoge obtained his undergraduate degree from Amherst College and a doctorate from The University of California, San Francisco in 2003. |
| Elizabeth G. Nabel |
Elizabeth G. Nabel currently works at The Boys & Girls Clubs of Boston, Inc., as Director from 2014, Accolade, Inc., as Independent Director from 2021, The Broad Institute, Inc., as Director from 2012, Lasker Foundation, as Director, Partners Medical International, Inc., as Director, Medtronic Plc, as Independent Director from 2014, Moderna, Inc., as Independent Director from 2021, Lyell Immunopharma, Inc., as Independent Director from 2021, Ariadne Labs, as Director from 2012, National Academy of Sciences, as Member, American Academy of Arts & Sciences, as Member, National Academy of Medicine (United States), as Member, Association of American Physicians, as Member, OPKO Health, Inc., as Chief Medical Officer from 2022, American Society of Clinical Investigation, as Member, Partners In Health, as Trustee-Emeritus, and Longwood Fund Management LLC, as Advisor. Dr. Nabel also formerly worked at Medtronic, Inc., as Independent Director from 2014 to 2015, National Heart, Lung & Blood Institute, as Director from 1999 to 2009, Moderna, Inc., as Independent Non-Executive Director from 2015 to 2020, abrdn Healthcare Investors, as Independent Trustee, abrdn Life Sciences Investors, as Independent Trustee, abrdn World Healthcare Fund, as Independent Trustee from 2018 to 2019, The Brigham & Women's Hospital, Inc., as President from 2010 to 2021, Modex Therapeutics Ltd., as Executive Vice President-Strategy from 2021 to 2022, Brigham & Women’s Physicians Organization, Inc., as President from 2010 to 2021, Harvard Medical School, as Professor from 2010 to 2021, Brigham & Women's, as President from 2010 to 2021, abrdn Healthcare Opportunities Fund, as Trustee, and Brigham, Inc. (Massachusetts), as President from 2010 to 2021. Dr. Nabel received her undergraduate degree from St. Olaf College and doctorate degree from Weill Cornell Medical College. |
| Sandra J. Horning |
Sandra J. Horning is the founder of EQRx International, Inc. (founded in 2020) and EQRx, Inc. (founded in 2019). She is currently an Independent Director at Gilead Sciences, Inc., Revolution Medicines, Inc., Olema Pharmaceuticals, Inc., Moderna, Inc., and Cellarity Inc. She is also a Professor at Stanford University School of Medicine. Previously, she held positions as a Director at Foundation Medicine, Inc. (2015-2018), Chief Medical Officer & EVP-Global Development at Genentech, Inc. (2014-2019), Chief Medical Officer at Roche Holdings, Inc. (2009-2019), President at American Society of Clinical Oncology, Inc. (2005-2006), and Chief Medical Officer & Head-Product Development at Roche, Inc. (2013-2019). Dr. Horning received her undergraduate and doctorate degrees from the University of Iowa. |
| Elizabeth E. Tallett |
Elizabeth E. Tallett currently works at Elevance Health, Inc., as Independent Chairman from 2018, Solebury School, as Chairman-Trustees Board from 2019, Principal Life Insurance Co., as Director from 1992, Museum of Contemporary Science, as Director, Promontory Therapeutics, Inc., as Director from 2021, Moderna, Inc., as Independent Director from 2020, QIAGEN NV, as Independent Member-Supervisory Board from 2011, QIAGEN GmbH, as Member-Supervisory Board, The University of Nottingham, as Member-Sports Board, and QIAGEN Srl, as Member-Supervisory Board. Ms. Tallett also formerly worked at Dioscor, Inc., as President & Chief Executive Officer from 1996 to 2003, Marshall Pharmaceuticals, Inc., as Chief Executive Officer from 2000 to 2003, Transcell Technology, Inc., as President & Chief Executive Officer from 1992 to 1996, Meredith Corp., as Lead Independent Director from 2020 to 2021, Warner-Lambert Co., as Director-Worldwide Strategic Planning, IntegraMed America, Inc., as Independent Director from 1998 to 2012, Principal Financial Group, Inc., as Independent Director from 2019 to 2021, Coventry Health Care, Inc., as Lead Independent Director from 2011 to 2013, Varian, Inc., as Director from 2001 to 2010, Varian Semiconductor Equipment Associates, Inc., as Director, Immunicon Corp., as Director from 1998 to 2008, Hepregen Corp., as Director, Qiagen, Inc., as Director, BioNJ, Inc., as Founding Director, Y-Prime LLC, as Director, Centocor, Inc., as President, Hunter Partners LLC, as Principal from 2002 to 2015, and Centocor Biologics LLC, as President. Ms. Tallett received her undergraduate degree in 1970 from The University of Nottingham. |
